Gene Patenting, the Supreme Court’s Myriad Decision, and the Future of Biotechnology

A Panel Discussion
Moderated by Dean Martha Minow of Harvard Law School, this panel will focus on the impact of the Supreme Court’s recent decision in the Myriad case that naturally occurring DNA cannot be patented. Will this be a boon for patients and a burden for biotech companies? Will sufficient incentive remain for innovation? Will there be any practical change at all? Panelists will include:
Cosponsored by the Broad Institute of MIT and Harvard.